Abstract:Introduction: Peripheral arterial disease (PAD) is caused by atherosclerosis. PAD is a common disease that affects 12% of the adult population and causes significant morbidity and mortality. The existing treatments for PAD, including pharmacological, interventional and surgical procedures, are not sufficient and many patients are opt for limb amputation. Therapeutic angiogenesis using angiogenic factors has been considered to be a potential treatment option for PAD patients. Hypothesis: In this study, we assessed the potential of a new angiogenic factor AGGF1 for therapeutic angiogenesis in a critical limb ischemia model in mice for PAD. Methods and Results: We generated a unilateral hindlimb ischemia model in mice by ligation of the right common iliac artery and femoral artery. Ischemic mice with intrasmuscular administration of DNA for an expression plasmid for human AGGF1 ( AGGF1 group) resulted in increased expression of both AGGF1 mRNA and protein after the administration compared with control mice of hindlimb ischemia with injection of the empty vector (control group). The blood flow in ischemic hindlimbs was significantly increased in the AGGF1 group compared to control mice at time points of 7, 14, and 28 days after DNA administration. Four weeks after the injection of DNA, the blood flow was approximately 2.19 fold higher in AGGF1 group than that in control. With the increased blood flow in the AGGF1 group, ambulatory impairement were inhibited compared with the control group. Increased AGGF1 expression decreased necrosis in muscle tissues injected with AGGF1 DNA compared with the control tissue injected with the empty vector. CD31-positive capillary vessel density was significantly higher in AGGF1 -injected limbs than in empty vector-injected limbs. Conclusions: These data establish that plasmid DNA-based gene transfer of AGGF1 into mouse skeletal muscles is efficient in increase the expression levels of AGGF1 mRNA and protein. Increased AGGF1 expression increases blood flow by increasing density of CD31-positive vessels and by decreasing necrosis in muscle tissues. These findings suggest that AGGF1 may be used as a candidate therapeutic agent for therapeutic angiogenesis to treat PAD.

Pluronic (R) L64-Mediated Stable Hif-1 Alpha Expression in Muscle for Therapeutic Angiogenesis in Mouse Hindlimb Ischemia

Partial Restoration of Left Ventricular Systolic Function by asPLB Gene Transfer Using Ultrasound-Mediated Microbubble Destruction

Polymeric Nanostructure Compiled with Multifunctional Components to Exert Tumor-Targeted Delivery of Antiangiogenic Gene for Tumor Growth Suppression

Therapeutic Angiogenesis by a "Dynamic Duo": Simultaneous Expression of HGF and VEGF165 by Novel Bicistronic Plasmid Restores Blood Flow in Ischemic Skeletal Muscle

Electroneutralized amphiphilic triblock copolymer with a peptide dendron for efficient muscular gene delivery

Safe and Efficient Local Gene Delivery into Skeletal Muscle Via a Combination of Pluronic L64 and Modified Electrotransfer.

Prolyl hydroxylase domain-2 silencing induced by hydrodynamic limb vein injection enhances vascular regeneration in critical limb ischemia mice through activation of multiple genes.

The Proper Strategy to Compress and Protect Plasmid DNA in the Pluronic L64-electropulse System for Enhanced Intramuscular Gene Delivery

"All in one" lipid-polymer nanodelivery system for gene therapy of ischemic diseases

A Low-Molecular-Weight Polyethylenimine/pDNA-VEGF Polyplex System Constructed in a One-Pot Manner for Hindlimb Ischemia Therapy.

Synergistic Effects of FGF-2 and PDGF-BB on Angiogenesis and Muscle Regeneration in Rabbit Hindlimb Ischemia Model

Angiogenesis Effect on Rat Liver after Administration of Expression Vector Encoding Vascular Endothelial Growth Factor D

Biodegradable Carriers for Delivery of VEGF Plasmid DNA for the Treatment of Critical Limb Ischemia

Polyethylene glycol-poly(ε-benzyloxycarbonyl-l-lysine)-conjugated VEGF siRNA for antiangiogenic gene therapy in hepatocellular carcinoma.

RGD-Modified Nanocarrier-Mediated Targeted Delivery of HIF-1α-AA Plasmid DNA to Cerebrovascular Endothelial Cells for Ischemic Stroke Treatment.

Peptide-based Vector of VEGF Plasmid for Efficient Gene Delivery in Vitro and Vessel Formation in Vivo.

Sustained Release of Plasmid DNA from PLLA/POSS Nanofibers for Angiogenic Therapy

Abstract 216: Angiogenic Factor AGGF1 Promotes Therapeutic Angiogenesis in a Mouse Limb Ischemia Model for Peripheral Arterial Disease

Plasmid containing VEGF-165 and ANG-1 dual genes packaged with fibroin-modified PEI to promote the regeneration of vascular network and dermal tissue

Changes in ischemic skeletal muscle of the limbs in diabetic rats after multi-point injection of recombinant plasmids carrying hepatocyte growth factors into the skeletal muscles around the femoral arteries

A thermosensitive hydrogel-copper meta-organic framework composite improves hindlimb ischemia therapy through synergistically enhancing HIF-1α production and inhibiting HIF-1α degradation